Susquehanna International Group’s INmune Bio INMB Stock Holding History

Susquehanna International Group’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.4K	Sell	31,300 -27,700	-47%	-$39.5K	﹤0.01%	12723
2025 Q4	$92K	Sell	59,000 -96,600	-62%	-$172K	﹤0.01%	11498
2025 Q3	$322K	Sell	155,600 -160,500	-51%	-$367K	﹤0.01%	9944
2025 Q2	$730K	Buy	316,100 +259,300	+457%	+$1.9M	﹤0.01%	8254
2025 Q1	$444K	Buy	56,800 +31,700	+126%	+$252K	﹤0.01%	9156
2024 Q4	$117K	Buy	+25,100	New	+$131K	﹤0.01%	11217
2024 Q3	–	Sell	-39,400	Closed	-$348K	–	12470
2024 Q2	$348K	Buy	+39,400	New	+$388K	﹤0.01%	9129
2024 Q1	–	Sell	-24,600	Closed	-$277K	–	12712
2023 Q4	$277K	Sell	24,600 -14,100	-36%	-$118K	﹤0.01%	9988
2023 Q3	$265K	Buy	38,700 +4,900	+14%	+$40.6K	﹤0.01%	9634
2023 Q2	$307K	Buy	+33,800	New	+$271K	﹤0.01%	9387
2022 Q4	–	Sell	-19,600	Closed	-$122K	–	13007
2022 Q3	$122K	Buy	+19,600	New	+$172K	﹤0.01%	11500
2021 Q4	–	Sell	-42,900	Closed	-$833K	–	13472
2021 Q3	$833K	Buy	+42,900	New	+$828K	﹤0.01%	8030

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Susquehanna International Group's INMB Position: Q1 2026 in Review

Susquehanna International Group reduced its INmune Bio (INMB) stake by 23% in Q1 2026, selling an estimated $80.5K and leaving 194,391 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #11508.

Susquehanna International Group first reported a position in INMB in Q1 2020 and has held it in 20 quarters since. The position peaked at $1.82M in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Susquehanna International Group held 194,391 shares of INmune Bio worth $220K as of Q1 2026.
Susquehanna International Group sold 56,519 INmune Bio shares in Q1 2026, an estimated $80.5K.
INmune Bio made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11508 holding.
Susquehanna International Group first reported a position in INmune Bio in Q1 2020 and has held it in 20 quarters since.
Susquehanna International Group's INmune Bio position peaked at $1.82M in Q1 2024.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.